2004•Huaxi yixueRequires access

Analysis on the Hospital Infections Due to Extended Spectrum Batalaclose-Producing Bacteria

Liu Jia-rui

Open publisher page 0 citations

Abstract

Objective;To investigate the incidence rate and distributed condition of the hospital infections due to extended spectrum batalaclose(ESBLs)-producing bacteria and the antibiotic resistance characterisation of the bacteria in our hospital.Methods:The ESBLs-producing bacteria assays were perfoumed with double-disk synergy test and compunud piece type confirm test.The bactrea identification and drug sesitivity tests were performed weith france bioMerieux-API identification system and K-B method,respectively.Result:Among 480 strains gram-negative bacilli,135 strains were ESBLs-producig bacteria(28.13%).Escherichia coli and klebasiella pneumoniae accounted for 24.89% and 35.34% of the ESBLs-producing bacteria,respectively,The antibiotic resistance rate of ESBLs producign bacteria was significantly higher than the non-ESBLs-producing bacteria(P0.01).The resistance strains to imipenem were not detected.Conclusion:The ESBLs assay should routinely be done in the clinical laboratory bacteria identification,it s helpful to control the spread and epidemic of ESBLs-producing bacteria.Imipenen is first selected drug for treat ESBLs-producing bacteria infections.

About this research paper

What this paper is about

Objective;To investigate the incidence rate and distributed condition of the hospital infections due to extended spectrum batalaclose(ESBLs)-producing bacteria and the antibiotic resistance characterisation of the bacteria in our hospital.Methods:The ESBLs-producing bacteria assays were perfoumed with double-disk synergy test and compunud piece type confirm test.The bactrea identification and drug sesitivity tests were performed weith france bioMerieux-API identification system and K-B method,respectively.Result:Among 480 strains gram-negative bacilli,135 strains were ESBLs-producig bacteria(28.13%).Escherichia coli and klebasiella pneumoniae accounted for 24.89% and 35.34% of the ESBLs-producing bacteria,respectively,The antibiotic resistance rate of ESBLs producign bacteria was significantly higher than the non-ESBLs-producing bacteria(P0.01).The resistance strains to imipenem were not detected.Conclusion:The ESBLs assay should routinely be done in the clinical laboratory bacteria identification,it s helpful to control the spread and epidemic of ESBLs-producing bacteria.Imipenen is first selected drug for treat ESBLs-producing bacteria infections.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective;To investigate the incidence rate and distributed condition of the hospital infections due to extended spectrum batalaclose(ESBLs)-producing bacteria and the antibiotic resistance characterisation of the bacteria in our hospital.Methods:The ESBLs-producing bacteria assays were perfoumed with double-disk synergy test and compunud piece type confirm test.The bactrea identification and drug sesitivity tests were performed weith france bioMerieux-API identification system and K-B method,respectively.Result:Among 480 strains gram-negative bacilli,135 strains were ESBLs-producig bacteria(28.13%).Escherichia coli and klebasiella pneumoniae accounted for 24.89% and 35.34% of the ESBLs-producing bacteria,respectively,The antibiotic resistance rate of ESBLs producign bacteria was significantly higher than the non-ESBLs-producing bacteria(P0.01).The resistance strains to imipenem were not detected.Conclusion:The ESBLs assay should routinely be done in the clinical laboratory bacteria identification,it s helpful to control the spread and epidemic of ESBLs-producing bacteria.Imipenen is first selected drug for treat ESBLs-producing bacteria infections.

Key concepts: Bacteria, Imipenem, Microbiology, Medicine, Drug resistance, Antibiotics, Klebsiella pneumoniae, Virology

Related papers

Back to paper searchBrowse research topicsOriginal source
Analysis on the Hospital Infections Due to Extended Spectrum Batalaclose-Producing Bacteria — Research Paper | ScholarLens